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Short title Breath analysis of children with type 1 diabetes
Abstract: A pilot study of exhaled volatile compounds and their correlation with
blood glucose levels in eight children with type 1 diabetes is reported. Five paired
blood and breath samples were obtained from each child over a 6 hour period. The
blood glucose concentration ranged from 41.4 to 435.6 mg/dL. Breath samples were
collected in Tedlar® bags and immediately evacuated through thermal desorption
tubes packed with Carbopack B and C. The VOCs were later recovered by thermal
desorption and analysed using gas chromatography mass spectrometry. The study
identified 74 volatile compounds present in at least 10% of the patient samples. Of
these 74 volatiles 36 were found in all patient samples tested. Further analysis of the
36 compounds found that none showed significant overall correlation with blood
glucose levels. Isoprene showed a weak negative correlation with blood glucose
levels. Acetone was found to have no correlation with blood glucose levels for the
patients studied. Some patients showed significant individual correlation between the
relative peak areas of certain compounds and blood glucose levels. However, there
was no consistent pattern observed within these results across all 8 patients.
Additional breath samples were collected in Tedlar® bags and analysed using SIFT-
MS for 3 of the patients and a healthy control. The levels of 24 volatiles are reported
and were found to be generally consistent with previously reported SIFT-MS data. In
agreement with the GCMS data, no compounds exhibited a significant overall
correlation with blood glucose level. Acetone exhibited a negative correlation with
blood glucose but this could largely be attributed to higher levels in the control versus
the patient group. Again, some patients and the control exhibited individual
correlations between the concentration of VOCs and blood glucose levels. However,
the findings were not completely consistent with the GCMS data.
This study found a lack of correlation between breath VOCs and blood glucose levels
using two methods. Further work involving larger numbers of diabetic children
stratified according to age, sex and disease duration/ history would be required in
order to confirm these findings.
Confidential: not for distribution. Submitted to IOP Publishing for peer review  13 February 2013
1. Introduction
Type 1 diabetes is a major health problem. The current prevalence of Type 1 diabetes in
children in the UK is one per 700–1,000 [diabetes.org.uk]. Good glycaemic control, by
regular blood glucose monitoring, is the cornerstone of type 1 diabetes management. It
reduces the risk of long-term micro- and macro-vascular complications [White et al. 2001]
and helps to prevent hypoglycaemia. Self-monitoring protocols are vital to improved long-
term control in childhood diabetes [Rosilio et al. 1998 and Craig et al. 2007]. However, this is
hampered by poor adherence [Hermansson et al. 1986], in part due to pain from lancet
sampling to test blood glucose [Burge et al. 2001]. Needle phobia has a prevalence of at least
10% in the general population [Hamilton, 1995], but in children with diabetes the prevalence
may be as high as 27% [Simmons et al. 2007]. Attempts to reduce pain by making shallower
puncture sites had a limited impact on patient acceptability [Pecaud et al. 1999]. Needleless
devices have been trialled but long-term acceptance is poor as a result of inconvenience, pain
and skin irritation [Weinzimer et al. 2009]. Much effort has been focussed on the
development of alternative methods of continuous glucose monitoring [Ferrante do Amaral
and Wolf 2008] but they are not being used to replace self-monitoring in children. A non-
invasive, non-traumatic test for estimating blood glucose concentration would prove more
acceptable to diabetics, particularly children.
The measurement of exhaled volatile compounds could have many advantages over current
blood glucose monitoring methods, if a marker compound that is predictive of blood glucose
could be identified. Acetone [Wang et al. 2010], ethanol (in combination with acetone)
[Galassetti et al. 2005], carbon monoxide [Paredi et al. 1999] methyl nitrate [Novak et al.
2007], C4–C20 alkanes and monomethylated alkanes [Phillips et al. 2004] have each been
reported to correlate with blood glucose in adults.
Wang et al. [Wang et al. 2010] utilised cavity ringdown spectroscopy to analyse the breath of
34 patients with type 1 diabetes, 10 with type 2 diabetes and 15 healthy controls; they found
no overall correlation between breath VOCs and blood glucose or blood glycohaemoglobin
A1c (HbA1c) in type 1 diabetics. Deng et al. developed a solid-phase micro-extraction
(SPME) method involving an on fibre derivatisation of acetone to acetone oxime for the
accurate determination of breath acetone levels [Deng et al.2004]; they used the method to
measure the breath acetone concentrations of 15 patients with type 2 diabetes and 15 controls
but did not link the analysis to blood glucose levels.
Selected ion flow tube - Mass spectrometry (SIFT-MS), due to its direct sampling capabilities
and accurate quantification selected ion flow tube, has been used extensively for the
measurement of breath acetone and other VOCs in both healthy individuals [Dummer et al.
2010 and Spanel et al. 2007] and patients with type 1 [Turner et al. 2009] and type 2 [Storer
et al. 2011] diabetes. Proton-transfer mass spectrometry (PTRMS) has been used to measure
the breath acetone concentrations in 243 healthy volunteers [Schwarz et al. 2009].
This report concerns a GC-MS and SIFT-MS study of exhaled volatile compounds from the
breath of children with type 1 diabetes. The measured levels of these volatiles were correlated
with blood glucose levels to assess their potential as non-invasive markers of blood glucose
concentration in this age group.
2. Experimental
2.1. Patients and approval
Eight children (aged 6 to 16 years) (Table 1) with type 1 diabetes were invited to participate
in the study. Ethical approval was granted by Salisbury and Wiltshire Research Ethics
Committee and clinical research governance approval and sponsorship granted by the host
institution. An age matched healthy control was also recruited (age 11 years). Informed
consent was obtained from the parents of participants.
Table 1. Age and gender of patients and control.
Sex/ID Age BMI Insulin regime Insulin
dose/kg
Duration
of diabetes
(years)
HbA1c
(mmol/mol)
Years Months
F 1 16 4 32.4 Insulin pump 1.1 8.8 58
F 2 15 5 24.1 Basal/bolus 1.5 8.5 n/a*
F 3 14 6 20.1 Basal/bolus 1.0 1.9 52
M 1 13 10 19.7 Basal/bolus 1.0 5.4 60
M 2 13 0 17.9 Basal/bolus 0.9 8.6 48
M 3 11 10 17.0 Basal/bolus 1.0 0.5 72
M 4 10 10 22.2 Basal/bolus 1.3 4.3 68
M 5 6 6 15.0 BD mixed insulin 0.6 1.8 54
*this patient is Hb Punjabi (fructosamine level 317 micromol/l) equivalent to HbA1c of 53mmol/mol
2.2. Clinical procedures
Clinical procedures were carried out in the clinical research unit at the Bristol Royal Hospital
for Children. Serial blood samples were drawn at 90-minute intervals, via an intravenous
cannula. Glucose concentration was determined using the hexokinase method [Tietz 1995] in
the clinical chemistry laboratory of the hospital. The blood glucose of each participant was
permitted to vary according to his or her usual self-management: snack refreshments were
provided at 10:00 and 14.30 (sugar-free squash, apples, crisps and biscuits) and lunch was
provided at 12:00.
2.3 Breath VOC collection
The children had breakfast prior to attending the research unit. A blood and breath sample
was collected from each child at 5 points during the day (Table 2). The samples were paired,
immediately following the collection of a blood sample a breath sample was also collected.
Breath was collected by exhalation through a PTFE mouthpiece into a 3 litre Tedlar® bag
(Adtech, UK) until it was full, then the bag was closed. Each child was asked to inhale and
then exhale fully into the bag to provide a full vital capacity sample. Turner et al. (2009)
found that measured concentrations of acetone in whole breath using a similar method were
close to those measured in alveolar breath. It should be noted that for certain compounds it is
known that the route of expiration can affect the concentration. For example it was found that
ammonia, ethanol and hydrogen cyanide concentrations were significantly lower in nose-
exhaled breath compared to mouth-exhaled breath [Wang et al. 2008]. We adopted the
sampling methodology of a full vital capacity sample via the mouth as it was easily tolerated
by the patients and enabled collection of the required volume in a short time period.
The bags were flushed with scrubbed nitrogen 3 times to remove any contamination prior to
their use. A control sample was taken using nitrogen gas stored in a Tedlar® bag on each
study day to assess contamination; this showed the presence of phenol and N,N-
dimethylacetamide on each occasion, as expected [Steeghs et al. 2007]. To minimise the
potential loss of volatiles by partitioning [Groves and Zellers 1996], all samples were
evacuated from the bags, onto collection tubes, immediately following their collection.
The collection tubes (PerkinElmer, UK) were empty glass tubes packed with Carbopack B
and C (Sigma Alrich, UK) adsorbent, selected for their ability to reversibly trap a wide range
of VOCs. These were used with the PerkinElmer TurboMatrix TD 50 automated thermal
desorption (ATD) system. Each tube was conditioned using the ATD system at a temperature
of 350oC and run via GCMS prior to use to test for contaminants. During transportation to and
from the hospital the clean tubes were sealed to air using brass Swagelock® storage caps with
PTFE ferrules.
The breath filled Tedlar® bag was connected via a clean collection tube to an in-house built
bag evacuation device designed to evacuate 2 litres of gas through the collection tube at a
constant flow rate of 350 ml min-1  in order to pre-concentrate the VOCs. The tube was then
re-sealed with the Swagelok® storage caps until analysis by GC-MS. All samples were
analysed within 24 hours of collection. Room air control samples, collected directly onto
collection tubes were also obtained.
An additional breath sample, in a separate Tedlar® bag, was obtained from three patients (F1,
M5 and M4) for analysis by SIFT-MS. These bags were taken to the laboratory and analysed
on the same day.
2.4. GC-MS method
The analyses were undertaken on a Perkin Elmer Clarus 500 quadrupole GC/MS (Perkin
Elmer, Beaconsfield, UK) coupled to a TurboMatrix TD50 thermal desorption unit. Pure
helium carrier gas of 99.9995% (BOC, Guildford, UK) was passed through a helium
purification system, ExcelasorbTM (Supelco, Poole, UK) at 1.1 ml min-1. The GC column
was a 60 metre long Zebron ZB-624 capillary GC column with an inner diameter of 0.25 mm
and a film thickness of 1.4 µm. The system parameters were set as follows:
ATD
Carrier gas – helium (scrubbed)
Head pressure – 44.6 psi
Reverse dry purge – 10 minutes at 90 ml min-1with helium
Primary desorption – 280°C for 20 minutes at 60 ml min-1with helium
Inlet Split – off
Outlet split – off
Secondary desorption – 310°C for 4 minutes
Transfer line – 250°C
GC
Initial temperature – 35°C with a 1 minute hold
Temperature ramp 1 – 7°C min-1 to 100°C with no hold
Temperature ramp 2 – 4°C min-1 to 200°C with no hold
Temperature ramp 3 – 20°C min-1 to 220°C with 12 minute hold
MS
Initial delay – 3.5 minutes
Ionisation mode – EI, 70eV
Scan Mode – 10–300 m/z
Scan time – 0.3 sec
Dwell time – 0.05 sec
2.5 SIFT-MS method
The analysis was undertaken using a SIFT-MS Voice 200 instrument (Syft Technologies Ltd.
Christchurch, NZ). For a detailed description of the Voice 200 instrument and operation refer
to Prince et al. 2010. For a detailed description of SIFT-MS technology refer to [Smith and
Spanel 2005]. PrecursorH3O+, NO+ and O2+ions are generated from a microwave air./water
discharge at 0.5 Torr. A specific mass is selected by the upstream quadrupole mass filter and
then the selected ionic species are injected into fast flowing helium carrier gas in a flow tube
reactor. The sample is introduced to the flow tube and measurement of the counts per second
of the precursor ions and the resulting product ions is performed via the downstream
quadrupole mass filter and ion counting system (m/z range 10-300 amu).The SIFT-MS
instrument was used in multiple ion monitoring mode (MIM) for these experiments, the count
rate of selected ions of interest over a pre-defined time period being utilised for real time
quantification of certain pre-selected compounds. Breath samples collected in Tedlar® bags
from 3 patients with type 1 diabetes and a healthy control were introduced into the flow tube
of the SIFT-MS at a controlled flow rate (10sccm) via a heated (373K) variable leak valve at
the sample inlet. Each sample bag was attached directly to the SIFT-MS sampling line by
pushing the connection needle through a septum located on the bag’s spigot valve. All
samples were analysed within 6 hours of being produced by the patients. The samples were
analysed in the order they were produced by the patients. Once connected to the sample line
four discrete samples were taken from each sample bag, each of these was designed to detect
and quantify specific groups of compounds. The masses of the ion fragments used to quantify
each compound are listed after the compound name. Where two fragments of the same mass
were used to quantify a given compound then the relevant precursor ion is also noted. The
groups were made up of the following compounds:
Group A – heptane (m/z 60 (C2H5NOH+), 74 (C3H7NOH+), 99 (C7H15+) (heptane/NO+), 99
(C7H15+) (heptane/H3O+), 119 (H3O+.C7H16)), acetone (m/z 59 (C3H7O+)), 1-butanol (m/z 73
(C4H9O+)) , benzene (m/z 78 (C6H6+) (benzene;O2+), 78 (C6H6+) (benzene;NO+), 108
(NO.C6H6+)), ammonia (m/z 17 (NH3+), 18 (NH4+)), isoprene (m/z 53 (C4H5+), 67 (C5H7+), 68
(C5H8+) (isoprene;O2+), 68 (C5H8+) (isoprene;NO+), 69 (C5H8.H+)), hexane (m/z 105
(H3O+.C6H14)), acetaldehyde (m/z 32 (C2H4O+), 43 (CH3CO+), 45 (C2H5O+))  
Group B – butanone (m/z 72 (C4H8O+), 102 (NO+.C4H8O)), 1-propanol (m/z 42 (C3H6+), 31
(CH3O+), 59 (C3H7O+), 43 (C3H7+), 61 (C3H9O+)), toluene (m/z 92 (C7H8+) (toluene;O2+), 92
(C7H8+) (toluene;NO+), 93 (C7H8.H+)), propane (m/z 28 (C2H4+), 29 (C2H5+), 44 (C3H8+), 43
(C3H7+)), butanoic acid (m/z 73 (C2H4COOH+), 88 (C3H7COOH+), 60 (CH3COOH+), 71
(C3H7CO+) (butanoic acid;NO+), 118 (NO+.C3H7COOH), 71 (C3H7CO+) (butanoic acid;H3O+),
89 (C3H7COOH2+)), nitric oxide (m/z 30 NO+)), 2-heptanone (m/z 58 (C3H6O+), 71 (C5H11+),
114 C7H14O+, 144 (C7H14O.NO+), 115 (C7H14OH+))  
Group C – -pinene (m/z 107 (C8H11+)), heptanal (m/z 113 (C7H13O+), 115(C7H15O+)),
hexanal (m/z 72 (C4H8O+), 99 (C6H11O+), (101 (C6H13O+), methanol (m/z 33 (CH5O+)),
nonane (m/z 147 (C9H20.H3O+)), 2-pentanone (m/z 116 (NO+.C5H10O)), acetic acid (m/z 60
(CH3COOH+), 90 (NO+.CH3COOH), 61(CH3COOH2+) and p-xylene (m/z 91(C7H7+),
106(C8H10+)) 
Group D – ethanol (m/z 45 (C2H5O+) (ethanol;O2+), 46 (C2H6O+ (ethanol;O2+), 45 (C2H5O+)
(ethanol;NO+), 47 (C2H7O+)).
The compounds in each group were quantified over a 60 second period. The grouping of the
compounds in this way was undertaken to minimise overlap between the selected ions of
target compounds. This negates certain potential ionisation conflicts which could adversely
affect the accurate quantification of the target compounds. The list of the 24 pre-selected
compounds and their concentration (ppb) in the patient samples is displayed in Table 5.
3. Results and Discussion
3.1 Blood glucose
The blood glucose concentration demonstrated a wide degree of both subject and group
variation with a total range of between 41.4 and 435.6 mg/dL during the study (Table 2). The
HbA1c results displayed in Table 1 show that all subjects fall within the good to moderate
glycaemic control groups. (Range of values 48-72 mmol/mol, which equates to blood glucose
levels of 140.4-203.4mg/dL). The duration of disease spanned 0.5-8.8 years. The patients had
an average BMI of 21 (s.d 5.4), the majority of patients were in the healthy weight range.
Table 2. Time of blood glucose measurement and the result for individual patients
Time of blood
glucose
(mins)
Control
mg/dL 
 
F1
mg/dL 
 
F2
mg/dL 
 
F3
mg/dL 
 
M1
mg/dL 
 
M2
mg/dL 
 
M3
mg/dL 
 
M4
mg/dL 
 
M5
mg/dL 
0 70.2 180.0 185.4 165.6 126.0 183.6 131.4 340.2 297
90 68.4 288.0 57.6 102.6 198 64.8 75.6 226.8 226.8
180 91.8 309.6 41.4 91.8 158.4 90.0 59.4 187.2 122.4
270 86.4 189 147.6 88.2 190.8 136.8 48.6 361.8 360
360 88.2 154.8 52.2 115.2 126 145.8 68.4 300.6 435.6
3.2 GC-MS
Identification of the chromatographic peaks was carried out through spectral matching using
the National Institute of Standards and Technology (NIST) Library (05). In excess of 150
compounds were identified from the breath samples provided.
Table 3. Volatile organic compounds identified in the breath of 8 diabetic children
Compound name (CAS number) Occurrence
(max=40)
Occurrence (%
of total samples)
Acetaldehyde (75-07-0) 40 100
Acetic acid (64-19-7) 18 45
Acetone (67-64-1) 40 100
Allyl methyl sulfide (10152-76-8) 40 100
Benzene (71-43-2) 40 100
Butanal (123-72-8) 40 100
1-butanol (71-36-3) 40 100
2-butanol (78-92-2) 40 100
2-butanone (78-93-3) 40 100
Cis-1-ethyl-2methylcyclohexane (4923-77-7) 8 20
Cyclohexane (110-82-7) 40 100
Decane (124-18-5) 10 25
5,6 dimethyldecane (1636-43-7) 14 35
2,3-dimethylheptane (3074-71-3) 5 12.5
2,4-dimethylheptane ( 2213-23-2) 40 100
2,4-dimethyl-1-heptene (19549-87-2) 40 100
(1S)-6,6-dimethyl-2-methylene-bicyclo[3.1.1]heptane
(18172-67-3)
6 15
Dimethyl sulfone (67-71-0) 40 100
E,E-2,6-dimethyl-1,3,5,7-octatetraene (460-01-5) 5 12.5
Ethylbenzene (100-41-4) 40 100
3-ethylheptane(2216-32-2) 5 12.5
3-ethylhexane (619-99-8) 8 20
1-ethyl-3-methylbenzene (620-14-4) 36 90
Heptanal (111-71-7) 40 100
Heptane (142-82-5) 40 100
2-heptanone (110-43-0) 40 100
1-heptene (592-76-7) 23 57.5
1-hexadecyne (629-74-3) 4 10
1,1,1,3,3,3-hexafluoro-2-propanol ( 920-66-1) 4 10
Hexanal (66-25-1) 40 100
Hexane (110-54-3) 40 100
1-hexanol (111-27-3) 4 10
Isoprene (78-79-5) 40 100
Isopropyl alcohol (67-63-0) 40 100
Methacrolein (78-85-3) 40 100
Methanol (67-56-1) 40 100
2-methylbutane (78-78-4) 35 87.5
2-methyl-2-butanol (75-85-4) 5 12.5
2-methyl-3-buten-2-ol (115-18-4) 40 100
3-methyl-3-buten-1-ol (763-32-6) 22 55
3-methylheptane ( 589-81-1) 11 27.5
4-methylheptane ( 589-53-7) 40 100
3-methylhexane (589-34-4) 21 52.5
3-methyloctane (2216-33-3) 10 25
4-methyloctane ( 2216-34-4) 40 100
3-methylpentane 996-14-0) 4 10
2-methyl-1-pentene (763-29-1) 40 100
2-methyl-1-propanol (78-83-1) 38 95
1(methylthio) propane (3877-15-4) 18 45
1-(methylthio)- (E)-1-propene (24848-60-4) 32 80
Methyl vinyl ketone (78-94-4) 40 100
m-xylene (108-38-3) 40 100.0
n-hexyl acrylate (2499-95-8) 5 12.5
Nonane (111-84-2) 40 100
2,2,4,6,6-pentamethylheptane (13475-82-6) 15 37.5
Pentanal (110-62-3) 40 100
Pentane (109-66-0) 35 87.5
2-pentanone (107-87-9) 40 100
Pentylcyclopropane (2511-91-3) 12 30
beta-pinene (127-91-3) 40 100
Propanoic acid (79-09-4) 7 17.5
1-propanol (71-23-8) 40 100
1-propoxy-2-propanol (1569-01-3) 9 22.5
Propylbenzene (103-65-1) 16 40
p-xylene (106-42-3) 40 100
Styrene (100-42-5) 35 87.5
Tetrachloroethylene (127-18-4) 5 12.5
Toluene(108-88-3) 40 100
2,6,7-trimethyldecane (62108-25-2) 7 17.5
2,3,5-trimethylhexane (1069-53-0) 4 10
Unknown (10.93 mins) 11 27.5
Unknown (RT 11.42) 40 100
Unknown RT 13.88 min 11 27.5
Unknown RT 14.71 minutes 4 10
74 compounds were present in at least 10% of the patient samples (Table 3), 36 of these were
found to be present in 100% of the patient samples. Phenol and N,N-dimethylacetamide were
also found in all patient samples but are known contaminants of Tedlar® bags and are not
presented in Table 3 [Steeghs et al. 2007]. The ubiquitous compounds contain a series of 2-
substituted ketones including acetone, 2-butanone, 2-pentanone and 2-heptanone. Although 2-
hexanone was detected it was not present in 10% of the patient samples. The statistical
analysis focused on the 36 ubiquitous compounds. Table 4 shows the correlation coefficients
when the peak area values of the 36 ubiquitous compounds were compared to the blood
glucose levels for each patient at each time point. The overall correlation coefficient which
compares all patient blood glucose levels with the 40 measured peak area values for that
compound is also included. The correlation coefficients were calculated using the CORREL
function in Microsoft Excel.
Table 4. The Correlation of the peak area of 36 VOCs with the individual patients blood
glucose levels. The overall correlation between all measured peak area values for each VOC
and the matched blood glucose measurements is also included.
Compound Correlation coefficient
F1 F2 F3 M1 M2 M3 M4 M5 Overall
Acetaldehyde
-0.51 -0.02 -0.61 0.09 0.03 0.46 -0.71 0.67 0.3
Acetone 0.05 0.62 0.31 0.92 -0.38 -0.62 0.43 -0.39 -0.11
Allyl methyl sulphide 0.31 0.33 0.20 -0.40 0.30 0.71 0.55 -0.69 0.29
Benzene 0.42 -0.50 -0.05 -0.35 0.21 -0.03 -0.58 -0.05 0.28
Butanal
-0.42 -0.16 -0.44 -0.29 0.71 0.88 -0.69 0.43 0.19
2-butanol
-0.29 -0.61 0.16 -0.04 0.77 -0.38 -0.74 0.07 0.01
2-butanone
-0.62 -0.17 0.74 -0.22 0.92 -0.40 -0.45 -0.28 -0.01
Cyclohexane 0.63 0.83 -0.39 -0.24 0.46 -0.54 -0.61 -0.84 -0.30
2,4-dimethyl-1-heptene 0.39 0.05 -0.67 -0.40 0.35 -0.23 -0.45 0.18 -0.24
2,4-dimethylheptane 0.47 -0.06 -0.62 -0.36 0.42 -0.39 -0.39 0.23 -0.25
Dimethyl sulfone 0.19 -0.50 -0.26 -0.34 0.03 -0.11 -0.88 0.37 -0.08
Ethylbenzene 0.10 0.78 -0.85 -0.67 0.08 0.23 -0.57 -0.24 -0.27
1-ethyl-3-methylbenzene 0.80 0.88 0.73 -0.47 0.92 -0.38 -0.24 0.07 -0.29
Heptanal
-0.54 -0.18 -0.33 -0.28 0.72 0.19 -0.55 0.54 0.19
Heptane 0.05 0.22 -0.70 -0.13 0.35 -0.59 -0.52 0.19 -0.11
2-heptanone
-0.38 -0.05 -0.70 -0.14 0.43 0.16 -0.97 0.45 0.26
Hexanal
-0.58 -0.27 -0.50 -0.30 0.50 0.64 -0.82 0.55 0.23
Hexane
-0.02 -0.03 -0.77 -0.12 0.42 -0.58 -0.30 0.28 -0.19
Isoprene 0.04 -0.82 -0.34 0.12 -0.08 -0.86 -0.76 -0.34 -0.49
Isopropyl alcohol
-0.26 -0.77 -0.09 0.35 -0.53 -0.25 0.09 -0.09 -0.45
Methacrolein 0.43 -0.71 0.17 0.95 0.17 0.16 -0.50 -0.27 0.37
Methanol
-0.44 -0.11 0.15 -0.10 0.75 0.85 -0.53 0.64 -0.13
2-methyl-3-buten-2-ol 0.11 -0.35 -0.32 -0.12 0.25 -0.70 0.52 0.11 0.22
4-methylheptane 0.56 0.13 -0.63 -0.34 0.32 -0.53 -0.41 0.24 -0.23
4-methyloctane 0.55 -0.05 -0.61 -0.43 0.36 -0.25 -0.39 0.00 -0.27
2-methyl-1-pentene 0.29 0.08 -0.52 -0.14 0.24 -0.53 -0.40 0.50 -0.14
Methyl vinyl ketone
-0.33 0.29 -0.61 -0.48 0.82 -0.95 -0.90 -0.07 -0.24
m-xylene
-0.11 0.55 -0.80 -0.85 -0.06 0.97 -0.58 -0.36 -0.29
Nonane 0.57 0.29 -0.79 -0.43 0.45 -0.50 -0.85 -0.61 -.35
Pentanal
-0.39 0.07 -0.63 -0.12 0.52 -0.11 -0.70 0.38 0.26
2-pentanone
-0.70 0.04 0.09 -0.41 0.80 -0.37 -0.47 0.03 -0.25
beta-pinene 0.38 -0.75 0.39 -0.56 0.73 -0.08 0.36 -0.60 -0.17
1-propanol
-0.26 -0.61 0.49 -0.09 0.14 -0.75 -0.27 0.54 0.02
p-xylene
-0.01 0.79 -0.31 -0.94 0.13 0.72 -0.44 -0.41 -0.27
Toluene 0.79 -0.03 -0.81 0.27 -0.16 -0.45 -0.89 -0.43 -0.41
Unknown (RT 11.42)
-0.08 0.46 -0.81 -0.29 0.56 -0.15 -0.89 -0.48 -0.06
Table 4 shows that none of the ubiquitous compounds shows a significant overall correlation
with blood glucose levels. Isoprene has the highest overall correlation with blood glucose,
exhibiting a slight negative correlation of -0.49. Acetone and other ketones showed no overall
correlation with blood glucose levels. Certain patients showed high individual correlations for
specific compounds. However, there was not a consistent pattern of positive or negative
individual correlations with respect to blood glucose for any of the compounds identified. If
an individual correlation value of 0.75 (or -0.75) is taken as being indicative of a significant
relationship between blood glucose levels and the peak area of the compound, then the
following compounds exhibited no significant correlation with the individual patients blood
glucose levels: acetaldehyde, 2-methyl-1pentene, 2-methyl-3-buten-2-ol, benzene, heptane,
allyl methyl sulphide, pentanal, 4-methylheptane, 2,4-dimethylheptane, 2,4-dimethyl-1-
heptene, 4-methyloctane and heptanal. This list of compounds contains none of the ketones
identified but 3/5 of the aldehydes and 5/6 of the straight chain or branched alkanes. In
addition it also contains allyl methyl sulphide, a volatile usually associated with the ingestion
of garlic. Isoprene has a negative correlation with blood glucose levels in 3 of the 8 patients
(M4, M3 and F2). 1-ethyl-3-methylbenzene has a positive correlation with blood glucose
levels for 3 of the 8 patients (M2, F2 and F1) and patient F3 has a positive correlation just
below the threshold. Methanol has a positive correlation with blood glucose for 2 of the
patients (M2 and M3). Nonane shows a negative correlation with blood glucose for 2 of the
patients (F3 and M4). Of the ketones acetone (M1), 2-butanone (M2) and 2-pentanone (M2)
show a positive correlation in only 1 patient. In contrast 2-heptanone exhibits a negative
correlation with blood glucose in patient M4. There were some compounds that showed both
negative and positive correlations with blood glucose levels for different patients. These
compounds include methyl vinyl ketone, toluene, m-xylene, cyclohexane, ethylbenzene and
p-xylene. These are mainly volatiles that might be associated with an exogenous source such
as the environment.
3.3 SIFT-MS
The SIFT-MS results for 24 compounds are displayed in Table 5. A control is included who
had well controlled blood glucose spanning a small range (mean 4.5, s.d. 0.6) when compared
with the patient group (mean 12.2, s.d. 4.98). The compounds present in the largest
abundance were acetone, ammonia, nitric oxide, -pinene, isoprene and the alcohols
methanol, ethanol and 1-propanol. The mean overall concentrations of these compounds
including both control and patient data were, acetone (279ppb), ammonia (243ppb), nitric
oxide (365ppb), -pinene (39.76ppb), isoprene (28.50ppb), methanol (72ppb), ethanol
(457ppb) and 1-propanol (96ppb). This compares well with literature values for acetone and
the other compounds measured using SIFT-MS. A large study of 243 individuals using
PTRMS [Schwarz et al. 2009] found that acetone concentrations ranged between 281-
1246ppb with a geometric mean of 544ppb. The same study considered a group of 44 children
(5-11years) whose median breath acetone level was 263ppb. Another study found that the
mean breath acetone concentration for young adults and children was 263ppb whereas for
adults aged 20-60 it was significantly higher at 477ppb [Spanel et al. 2007]. The same paper
found that the average ammonia level in young adults was 317 ppb rising to 833ppb in adults.
A study of breath isoprene in healthy volunteers [Turner et al. 2006] found the mean level
was 118ppb with a range of (0-474ppb). However, a study by Smith et al. [Smith et al. 2009]
focusing on breath isoprene levels in 200 healthy children found that the mean levels varied
with age (7–10 years (28 ± 24 ppb), 10–13 years (40 ± 21 ppb), 13–16 years (60 ± 41 ppb))
and were generally lower than the adult population. The distribution of the children’s data
were compared with data from an adult cohort also measured by SIFT-MS and the median
levels were 37ppb and 106ppb respectively. This data is in agreement with the data measured
in this study involving diabetic children in the age range 7-16. The mean levels of ethanol
(mean 196ppb, range 0-1663ppb) and acetaldehyde (mean 24ppb, range 0-104ppb) were
measured in 30 volunteers using SIFT MS [Turner et al. 2006b].
A study by Turner et al. [2009] involving 8 adults with type 1 diabetes found much higher
average levels of acetone than identified in this study. However, this fits with the age-related
results discussed above which highlight an increase in the mean breath acetone concentration
with age. It should also be noted that the diabetic patients in the study of Turner et al. had a
relatively long duration of disease (mean 28± 3 years) compared to this study involving
children (mean 5 years). It is interesting that the patients in this study show consistently low
breath acetone levels despite their blood glucose levels being over a large range (122.4-
435.6mg/dL). This is compared to the study of Turner et al. where the average breath acetone
concentration prior to insulin clamp was 5.5ppm and the range of baseline blood glucose
values was 86.4-250.2md/dL. It is possible that the observed differences are partly age-related
but could also be associated with the longevity of disease. It is likely that disease duration and
history of glycaemic control play a major role in altering the “normal” metabolism. This
highlights a problem with comparing the outcomes of breath volatile studies where cohorts
are made up of different age ranges. It also shows that age, gender, disease history etc. would
have to be factored into any developed test. However it should be noted that even though the
mean/median values obtained from these cohort studies often show differentiation the ranges
often overlap considerably. This type of compensation could potentially prove problematic
where such wide individual variation exists within groups.
The other ketones 2-butanone, 2-pentanone and 2-heptanone also observed in the ATD study
are present at very low mean concentrations, at 0.8ppb, 0.93ppb and 1.34ppb respectively.
This is in agreement with the ATD results where the peak area of acetone was 2-3 orders of
magnitude greater than the peak area of the other ketones.
There was no significant overall correlation between the concentration of any of the
compounds and the blood glucose levels. The highest overall correlation was observed for
acetone (-0.64). However, this negative correlation predominantly arises because the acetone
concentrations are significantly higher for the control than the patients. If the patients are
treated as an individual group then no overall correlation exists, in agreement with the GCMS
study. The mean value of acetone is 523 ppb for the control but only 198ppb for the patient
group. This can be compared with isoprene where the mean levels are lower in the control
(21.78ppb) than the patient group (30.74ppb), and also acetaldehyde where the mean values
are very well matched (control 27.28ppb, patient group 26.58ppb). The mean blood glucose
levels for the patients (219.6mg/dL) are higher than the control (81mg/dL) and the ranges do
not overlap. Therefore, the results may simply reflect “normal metabolism” where ketone
levels would be expected to be higher when blood glucose levels were lower. It is not possible
to be certain of the effect of low blood glucose without testing the patients over a lower range
of values using for example an insulin clamp regime to identify a definite link to metabolism
or indeed to identify a difference between adults with type 1 diabetes.
The mean acetone levels were found to be higher at the beginning of the day (340ppb) versus
the end of the session (168ppb). This is a consistent observation for the control and patient
groups and appears to be generally independent of blood glucose level (mean at beginning of
day 221.4mg/dL versus the mean at the end of the session 244.8mg/dL). A recent study by
Wang et al. [Wang CJ et al. 2010] of adults with type 1 diabetes and an earlier study by
Tassopoulos et al. [1969] found that acetone levels and blood glucose followed a cyclical
pattern during the day. Tassopoulos et al. found that breath acetone and blood glucose were
high in the morning and reached their lowest levels in the late afternoon. This agrees with our
observations for breath acetone concentrations. However, we did not identify a trend with
blood glucose. However, Wang et al. did identify that breath acetone peaks were often
delayed with respect to peaks in blood glucose levels with differences of up to 4 hours
observed for some patients. Therefore, a longer study in terms of time measurements and
including more patients may help establish a reliable trend. However, this complexity just
highlights further the difficulty in linking any compounds with blood glucose levels.
Presumably this differential time aspect exists for many compounds and varies depending on
the metabolic pathway involved.
Some of the subjects showed individual correlation with one or more of the VOCs and blood
glucose (see Table 6). Patient F1 again showed a positive correlation between toluene
concentration and blood glucose levels in agreement with the ATD study. However, positive
correlations were also observed for acetic acid, 2-butanone, 1-butanol, heptanal, nonane, 2-
pentanone, and p-xylene. Patient M5 again exhibited limited correlation with volatiles and
blood glucose levels in agreement with the ATD study.
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Table 6 showing the correlation of compounds detected by SIFT-MS and their relationship to
blood glucose
Compound Correlation coefficient
ConA F1 M5 M4 Overall
acetaldehyde 0.20 0.57 -0.45 -0.15 -0.06
acetic acid
-0.61 0.76 -0.38 -0.36 -0.54
acetone
-0.58 0.24 -0.60 -0.26 -0.64
ammonia
-0.56 0.23 0.59 -0.30 -0.32
benzene
-0.09 0.65 -0.09 0.00 -0.28
beta-pinene 0.56 0.74 -0.60 -0.06 -0.13
butanoic acid
-0.41 0.68 0.00 -0.11 -0.46
1-butanol
-0.33 0.81 -0.56 -0.52 -0.48
butanone
-0.40 0.93 -0.47 -0.46 -0.46
ethanol 0.45 0.67 0.37 0.16 0.09
heptanal
-0.74 0.79 -0.58 -0.46 -0.25
heptane 0.36 0.08 0.59 0.21 -0.14
2-heptanone
-0.25 -0.09 -0.45 0.11 -0.59
hexanal
-0.84 0.57 -0.86 -0.21 -0.32
hexane 0.20 0.68 0.11 0.14 -0.28
isoprene
-0.39 0.85 -0.99 -0.48 -0.09
methanol
-0.78 0.51 -0.53 -0.41 -0.50
nitric oxide
-0.27 0.90 -0.79 -0.46 -0.25
nonane
-0.56 0.93 -0.33 -0.52 0.53
2-pentanone
-0.79 0.83 -0.40 -0.55 -0.48
propane
-0.80 -0.27 -0.07 0.28 -0.04
1-propanol 0.61 0.46 -0.30 0.58 -0.09
p-xylene 0.37 1.00 -0.12 -0.97 -0.21
toluene
-0.69 0.96 -0.85 -0.65 -0.17
3.4 General discussion
A recent perspective article gives a very good summary of the state of the art with respect to
breath analysis and monitoring of diabetes [Smith et al. 2011].
Acetone is formed via the decarboxylation of acetoacetate and the dehydrogenation of
isopropylalcohol [Kalapos 2003]. Acetone and other ketone bodies are formed by the liver
during the metabolism of fatty acids. In the absence of readily available glucose this pathway
may predominate. Therefore, insulin dependent diabetics with poor glycaemic control are
susceptible to ketoacidosis a condition where high levels of ketone bodies (acetone,
acetoacetate and -hydroxybutyrate) are present in the blood and excreted in the urine. Breath
acetone levels have been reported to be higher in diabetes [Deng et al. 2004 and Nelson et al.
1998]. For example Deng et al. found that the median acetone concentration for healthy
controls was 520ppb and for type 2 diabetics it was 2260ppb whereas Nelson et al. found that
diabetic children had significantly higher levels of acetone than healthy controls. However, in
healthy individuals and controlled diabetics the generation of ketones represents the normal
physiological response to lower concentrations of blood glucose – “starvation ketones”. Thus
the concentration of breath acetone has been previously reported to be inversely related to the
concentration of blood glucose in healthy volunteers [Turner et al. 2008]. There is little
information available on breath acetone concentrations for diabetic patients in a non-ketotic
state. This study tested type I diabetics in the non-fasting state and found no overall
relationship between blood glucose and acetone concentrations and is consistent with other
studies where the baseline levels of acetone for each patient varied widely.
A number of studies have been undertaken to establish links between breath volatiles and
diabetes. Turner et al. [Turner et al. 2009] used SIFT-MS to study VOCs in 8 adults with type
1 diabetes patients tested under strict hypoglycaemic control. Each patient demonstrated a
positive relationship between acetone and blood glucose concentrations, although the range of
acetone levels varied widely between patients. In contrast this study involved children in a
non-fasting state who had a wide range of blood glucose readings. Wang [Wang C J et al.
2010] studied 34 patients with type 1 diabetes and found no overall correlation with breath
acetone. However, if the patients were grouped into 4 distinct classes according to their blood
glucose levels and the mean plotted then a positive relationship with breath acetone was
found. This study is in partial agreement with these results as it was observed that there was
no overall correlation when individual breath acetone results were compared with blood
glucose measurements.
Isoprene is commonly found in breath. There are several routes by which it is generated
including the mevalonic acid pathway of cholesterol [Buszewski et al. 2007]. It is known that
poor diabetic control is associated with dyslipidaemia but this is slow to emerge [Hallikainen
et al. 2006]. A study found there was no relationship between the concentration of exhaled
breath isoprene and serum cholesterol concentration [Buszewski et al. 2007]. Breath isoprene
is influenced by sex (it is higher in males) [Lechner et al. 2006] and was found to be
positively associated with age [Nelson et al. 1998]. Two studies have addressed the
relationship between breath isoprene and blood glucose [Turner et al. 2008 and Nelson et al.
1998]. Nelson et al. reported no difference between the amount of isoprene in exhaled breath
in healthy controls compared with those with diabetes, or between the level in diabetics in a
fasting or non-fasting/post insulin state. However, the 8 diabetic children studied were only
sampled once before and after food and no attempt was made to quantify any change in blood
glucose level, or to correlate this with changes in isoprene levels. Turner et al. found no
relationship between serum glucose and breath isoprene concentrations in healthy subjects.
The range of blood glucose levels prior to ingestion of glucose, was within the range 72–108
mg/dL, rising 2-fold after ingestion. This study identified a slight overall negative correlation
between breath isoprene and blood glucose levels in 8 diabetic children using ATD coupled
with GC-MS. The SIFT-MS data did confirm a slight negative correlation (for the patient
group) with isoprene concentration and blood glucose level. However, if the patient’s
individual correlations are considered then the picture is less clear with strong negative and
positive correlations observed between isoprene concentration and blood glucose. It is evident
that a larger study is required to clarify these findings with respect to isoprene.
Oxidative stress plays a central role in the onset of diabetes mellitus and the subsequent
development of vascular and neurological complications. It also likely to be a mechanism
causing changes in the exhaled VOCs measured in diabetic patients. Exhaled VOCs (C4–C20
n-alkanes and their monomethylated derivatives) have been studied in patients with type 1
and 2 diabetes mellitus [Phillips et al. 2004], showing that oxidative stress was significantly
and similarly increased in type 1 and type 2 diabetes mellitus but this increase appeared to be
independent of glycaemic control.
Methyl nitrate production is related to oxidative stress, which is regulated by insulin through
its modulation of lipolysis. Methyl nitrate was reported to be correlated with blood glucose in
children with type 1 diabetes [Novak et al. 2007]. Approximately 100 exhaled gas species
were defined and compared with plasma glucose concentrations and the VOC displaying the
greatest correlation with blood glucose levels was methyl nitrate. Exhaled methyl nitrate
concentrations closely matched plasma glucose levels in 16 out of the 18 subjects studied.
The characteristics of methyl nitrate formation suggest that rather than reflecting
hyperglycaemia per se, it may actually reflect the specific and complex pattern of metabolic
alteration that accompanies hyperglycaemia in type 1 diabetes mellitus. A further study by
Lee et al. [Lee et al. 2009] also showed a relationship between methyl nitrate concentration
and hyperglycaemia in young adults with type 1 diabetes. Our study failed to identify methyl
nitrate in the breath of diabetic children. Despite using pre-concentration the levels of methyl
nitrate (low ppt) are probably too low and require specialist methodology and detectors. We
were able to detect a standard of methyl nitrate at a higher concentration using GCMS so it is
just a problem with the limit of detection. Lee et al. [Lee et al. 2009] also found that acetone,
ethanol, xylene and ethylbenzene are correlated with hyperglycaemia. Exhaled ethanol is
associated with fermentation by gut flora and would be expected to be affected by an
increased hyperglycaemic state. It is assumed that aromatic hydrocarbons have an
environmental source but it is possible that levels are increased in the breath due to changes in
liver metabolism caused by hyperglycaemia. This study did not identify any correlation with
ethanol concentration on the breath of diabetic children. Levels were very variable for all the
subjects tested using SIFT-MS which could reflect changes due to consumption of food and
beverages. Individual correlations for a number of aromatic hydrocarbons were identified, 1-
ethyl-3-methylbenzene in particular showed a positive correlation with blood glucose levels
in 3 patients. In addition other patients were identified with individual correlations to xylene,
ethyl benzene and toluene although there were both negative and positive correlations within
this patient group.
This study was designed to identify markers or groups of markers that could be used to
provide a non-invasive basis for monitoring blood glucose levels. Despite many candidate
markers or groups of markers being identified previously, not least acetone, this study failed
to identify any definite correlation with these VOCs. The premise of this approach may be
accurate: volatile compounds may correlate with blood glucose. However, the target
compounds may be ill-advised. Ketones clearly rise in poorly controlled diabetes, but also
occur in starvation states, so a bell-shaped relationship may exist between ketones and
glucose; if this is true, then it is not surprising that linear modelling has failed to find an
association. The second flaw may be timing: after meals, diabetics may have a ‘glucose
excursion’ a rapid rise and, hopefully a fall, in glucose that is too short-lived for ketones to be
produced in response to the apparent insulin insufficiency. In contrast, sick diabetic patients
may be profoundly ketotic, without their blood sugar being especially high; ketosis is not
proportional to blood glucose.
The results do provide detailed information on a number of compounds and their correlation
(or lack thereof) with blood glucose levels over time. The results also give a comparison
between two methods, GCMS and SIFT-MS which are in general agreement with regard to
the main findings. Future work will aim to recruit larger numbers of patients and group them
according to age and glycaemic control (current and historical).
4. Conclusions
The breath of 8 children with Type 1 diabetes was analysed using GCMS. A total of five
breath samples and matched blood samples for glucose measurements were taken over a 6
hour period under hospital conditions. A total of 36 compounds was found to be present in all
patient samples analysed. None of these compounds was found to exhibit a significant overall
correlation with blood glucose. Isoprene showed a slight negative correlation overall with
blood glucose levels. Some compounds exhibited significant individual correlations with the
blood glucose levels of certain patients. However, there was no consistent pattern observed
within these results which would enable a sound discriminatory model to be developed.
A SIFT-MS study was also undertaken on a subset of the patients and a healthy control. The
levels of 24 compounds were monitored over time and compared with matched blood glucose
levels. Again no compound showed a significant overall correlation with blood glucose
levels. Acetone was found to be negatively correlated with blood glucose levels. However,
this result was affected by the fact that the control had higher mean levels of acetone and
consistently lower blood glucose. If the patient group were considered separately then no
overall correlation was observed. The levels of acetone measured for diabetic patients (mean
198ppb, S.D. 78ppb) are lower than generally reported in previous studies, although previous
work predominantly involved the study of adults with type 1 diabetes. However, this result is
in agreement with previous SIFT-MS and PTR-MS studies that found that the mean breath
acetone levels increase with age. Isoprene was again slightly negatively correlated with blood
glucose levels if just the patient data was considered. Although this study failed to identify
combinations of VOCs that may be useful for monitoring blood glucose levels, a more
extensive study of diabetic patients from specific age ranges and graded according to their
level of glycaemic control may facilitate firmer conclusions with respect to the viability of
breath testing in this application.
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